Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LuMIERE study of [177Lu]Lu-FAP-2286 in advanced solid tumors
2023-508995-12-01Phase 2Authorised
- Sponsor
- Novartis
- Start
- Dec 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of AAA614 in breast cancer, non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma (PDAC) (5 arms), sponsored by Novartis. Primary endpoints: Objective response rate and Safety and tolerability. Planned start Dec 2025; status: authorised.
02
Drugs
AAA614
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2023-508995-12-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508995-12-01.